Suppr超能文献

人体急性口服给药后苯妥英的蛋白结合及脑脊液穿透情况。

Protein binding and CSF penetration of phenytoin following acute oral dosing in man.

作者信息

Brodie M J, Muir S E, Agnew E, MacPhee G J, Volo G, Teasdale E, MacPherson P

出版信息

Br J Clin Pharmacol. 1985 Feb;19(2):161-8. doi: 10.1111/j.1365-2125.1985.tb02627.x.

Abstract

Prophylactic phenytoin (DPH) has been evaluated in 20 patients undergoing diagnostic myelography. DPH (0.75 g) was ingested at 20.00 h the night before and 0.5 g at 08.00 h on the morning of the procedure. Total DPH concentrations at myelography (mean +/- s.d.: 12.7 +/- 4.3 mg l-1; range 6.3-21.5 mg l-1) correlated with CSF values (1.3 +/- 0.46 mg l-1; range 0.7-2.2 mg l-1; r = 0.83, P less than 0.001). DPH protein binding at that time varied two-fold (9.2-18.5%) and free drug levels (1.7 +/- 0.6 mg l-1) correlated with CSF (r = 0.83, P less than 0.001) and total (r = 0.89, P less than 0.001) plasma DPH concentrations. There were significant negative correlations between patient weight (n = 17) and total (r = 0.57, P less than 0.05) and CSF (r = -0.55, P less than 0.05) DPH concentrations at myelography. Total plasma DPH levels 8 h (14.5 +/- 3.9 mg l-1; range 7.3-20.6 mg l-1) and 24 h (12.3 +/- 3.8 mg l-1; range 5.0-19.8 mg l-1) after myelography were largely within the 'therapeutic range' of 10-20 mg l-1 for the drug. No patient suffered a seizure although, in two, spike discharges were seen on a post-myelography electroencephalogram. A simple regime involving two doses of DPH would provide acceptable plasma CSF concentrations as a basis for controlled studies in seizure prophylaxis following neuroradiological investigations involving intrathecal contrast.

摘要

对20例行诊断性脊髓造影的患者进行了预防性苯妥英(DPH)评估。在检查前一晚20:00口服DPH(0.75 g),检查当天上午08:00口服0.5 g。脊髓造影时的总DPH浓度(均值±标准差:12.7±4.3 mg·l-1;范围6.3 - 21.5 mg·l-1)与脑脊液值(1.3±0.46 mg·l-1;范围0.7 - 2.2 mg·l-1;r = 0.83,P<0.001)相关。此时DPH的蛋白结合率变化两倍(9.2 - 18.5%),游离药物水平(1.7±0.6 mg·l-1)与脑脊液(r = 0.83,P<0.001)和血浆总DPH浓度(r = 0.89,P<0.001)相关。患者体重(n = 17)与脊髓造影时的总DPH浓度(r = 0.57,P<0.05)和脑脊液DPH浓度(r = -0.55,P<0.05)之间存在显著负相关。脊髓造影后8小时(14.5±3.9 mg·l-1;范围7.3 - 20.6 mg·l-1)和24小时(12.3±3.8 mg·l-1;范围5.0 - 19.8 mg·l-1)的血浆总DPH水平基本在该药物10 - 20 mg·l-1的“治疗范围”内。尽管有2例患者在脊髓造影后的脑电图上出现棘波放电,但无患者发生癫痫发作。一种包含两剂DPH的简单方案可提供可接受的血浆脑脊液浓度,作为在涉及鞘内造影剂的神经放射学检查后预防癫痫发作的对照研究基础。

相似文献

5
Plasma concentrations of 5-(4-hydroxyphenyl)-5-phenylhydantoin in phenytoin-treated patients.
Clin Pharmacol Ther. 1977 Mar;21(3):294-300. doi: 10.1002/cpt1977213294.
9
Plasma levels and renal excretion of phenytoin and its metabolites in patients with renal failure.
Clin Pharmacol Ther. 1979 Sep;26(3):306-14. doi: 10.1002/cpt1979263306.

本文引用的文献

2
Plasma protein binding of phenytoin in 100 epileptic patients.100例癫痫患者苯妥英钠的血浆蛋白结合情况
Br J Clin Pharmacol. 1982 Aug;14(2):298-300. doi: 10.1111/j.1365-2125.1982.tb01981.x.
5
Plasma protein binding and therapeutic drug monitoring.血浆蛋白结合与治疗药物监测。
Ther Drug Monit. 1980;2(1):29-37. doi: 10.1097/00007691-198001000-00005.
6
Clinical pharmacokinetics of cerebrospinal fluid.脑脊液的临床药代动力学
Clin Pharmacokinet. 1982 Jul-Aug;7(4):312-35. doi: 10.2165/00003088-198207040-00003.
8
Should we routinely measure free plasma phenytoin concentration?我们应该常规测量游离血浆苯妥英浓度吗?
Br J Clin Pharmacol. 1984 Jan;17(1):99-102. doi: 10.1111/j.1365-2125.1984.tb05007.x.
10
Variability of phenytoin protein binding in epileptic patients.癫痫患者中苯妥英蛋白结合的变异性。
Arch Neurol. 1983 Aug;40(8):481-3. doi: 10.1001/archneur.1983.04210070021007.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验